Background Elevated concentrations of low-density lipoprotein cholesterol (LDL-c) are a major risk factor for the development of coronary artery disease (CAD) because of their role in the progression of atherosclerosis. The black South African population is known to have had historically low LDL-c and in the past there was almost no CAD in the population. However, as this population moves through the nutrition transition, LDL-c levels are increasing. LDL-c levels are regulated by the LDL receptors, which is the major protein involved with transporting cholesterol across cell membranes in humans. Proprotein convertase subtilisinlike/kexin type 9 (PCSK9) is another protein involved with the regulation of LDL-c through its role in assisting with the degradation of the LDL receptor. Variants in both genes can cause elevated or lowered LDL-c levels. Very little information is available on the frequency or presence of variants in the low-density lipoprotein receptor (LDLR) and PCSK9 gene in the black South African population and on how these variants associate with LDL-c. The main aim of the study was thus to determine novel and existing genetic variants in these two genes and to describe the manner in which they associate with plasma LDL-c levels in a black South African population undergoing an epidemiological transition. Methods The 2005 baseline data from the Prospective Urban and Rural (PURE) study population were used in this study. The study population consisted of apparently healthy black volunteers form the North West province of South Africa, aged 35 to 60 years. Thirty individuals were randomly chosen from the 1860 volunteers to determine the presence of known and novel variants in these genes by automated bidirectional sequencing. The promoter region, exons and flanking regions were sequenced and variants were identified utilising CLC DNA Workbench. Deoxyribonucleic acid (DNA) samples for 1500 individuals of the PURE study population were genotyped by means of a Golden Gate Genotyping Assay. Analyses of covariance (ANCOVA) were used to test for associations between the different genotypes in both the LDLR and PCSK9 genes and LDL-c levels. Haplotypes were generated by using the confidence intervals on the software programme, HaploView. A genetic risk score (GRS) was determined by including variants which associated significantly with LDL-c. The GRS, the haplotypes and the variants that associated significantly with LDL-c were used in separate linear regression models with variants which correlated with LDL-c to determine how all these variables contribute to the differences in LDL-c levels. Results and discussion Novel and known variants were identified in both the genes and in total 52 variants were genotyped. Rare variants such as rs17249141 and rs28362286 were detected in the study population and are associated with low levels of LDL-c. The variants identified in the LDLR gene were situated largely in regulatory regions such as the promoter, intron and 3‟untranslated regions. Haplotypes in the LDLR gene with the highest frequency associated with lower LDL-c levels, which could contribute to the study population‟s low mean LDL-c level. Haplotypes identified in the PCSK9 gene had a weaker association with LDL-c levels. The minor allele frequencies of many of the variants differed from those of the European population and therefore the importance of population-specific research cannot be sufficiently emphasised. The GRS, haplotypes and variants used in the regression models to determine whether they contributed to predicting the variance in LDL-c in the study population made a small contribution to explaining this. BMI best explained the variance in LDL-c levels. Older women with a body mass index (BMI)>25kg/m2 were identified as being at greater risk of developing elevated LDL-c levels than the rest of the study population. Heterozygote carriers of variant, rs28362286, had 0.787 mmol/L lower LDL-c than carriers of the wild type and this is associated with a reduced risk of developing CAD. Conclusion and recommendation When considering the results mentioned above, adding genetic analysis to explaining the variance in LDL-c levels seems to have its limitations, but the study included only two of many genes that play a role in the metabolism and regulation of LDL-c levels. Incorporating more genes and more variants into analyses and prediction models will add greater value to defining LDL-c levels. Rarer variants with a large impact on protein function, such as rs28362286, have a greater effect on LDL-c levels and could predict the variance better than the common variants. Risk factors such as BMI can also still be trusted to indicate which individuals or groups are at risk of developing elevated LDL-c levels. Health advice should be given to appropriate target groups such as older women with a BMI >25kg/m2 in order to prevent CAD from becoming a burden in this population. / PhD (Dietetics), North-West University, Potchefstroom Campus, 2014

Οικογενής Υπερχοληστερολαιμία (FH) είναι η επικρατής αυτοσωμική νόσος, κατά την οποία τα επίπεδα χοληστερόλης στο αίμα είναι αυξημένα, εμφανίζονται ξανθώματα και ένα αυτοσωμικό επικρατές χαρακτηριστικό για στεφανιαία αρτηριακή νόσος (CAD). Η FH προκαλείται από ανωμαλία στο γονίδιο LDL-R και κάποιες φορές και στο γονίδιο APOB (apolipoprotein B-100). Η ετεροζυγία του LDLR συναντάται σε αναλογία πληθυσμού 1:500. Πρόσφατα παρατηρήθηκε ότι και το γονίδιο PCSK9 (proprotein convertase subtilisin/kexin type 9) προκαλεί FH. Τα γονίδια APOB και PCSK9 αποκλείστηκαν από τη συγκεκριμένη έρευνα. Στόχοι της διατριβής ήταν (α) η καταγραφή των μεταλλάξεων του γονιδίου LDLR (Low Density Lipoprotein Receptor) σε 21 πληθυσμούς, (β) ο υπολογισμός της συχνότητας αυτών των μεταλλάξεων και (γ) η προσθήκη αυτών των δεδομένων σε μία γενετική βάση δεδομένων, την FINDbase, η οποία δίνει πληροφορίες για τη συχνότητα μιας μετάλλαξης σε κάθε χώρα καθώς και το φαρμακευτικό δείκτη της. Από τους 21 πληθυσμούς, οι 14 προέρχονταν από Ευρωπαϊκές χώρες (Ελλάδα, Γερμανία,Πορτογαλία, Τσεχία, Ολλανδία, Ισπανία, Βρετανία, Ιταλία, Πολωνία, Σουηδία, Γαλλία, Αυστρία, Βέλγιο και Δανία) και οι υπόλοιποι από την Κίνα, την Ιαπωνία, την Μαλαισία, το Λίβανο, τις Φιλιππίνες, την Ταϊβάν και το Καναδά. Τα δεδομένα των μεταλλάξεων σε κάθε πληθυσμό αντλήθηκαν από άρθρα (papers) μέσω της Βάσης Δεδομένων Pubmed και της μηχανής αναζήτησης Google. Τα άρθρα επιλέχθηκαν με βάση (1) το μέγεθος του δείγματος και (2) τη χρονολογία πραγματοποίησης της έρευνας στο συγκεκριμένο πληθυσμό. Η συχνότητα υπολογίστηκε σε σύνολο χρωμοσωμάτων, δηλαδή στο διπλάσιο του μεγέθους του δείγματος. Ως ιδανικό μέγεθος δείγματος θεωρήθηκε ένα σύνολο τουλάχιστον 100 χρωμοσωμάτων, δηλ. 50 άτομα. Η καταγραφή των δεδομένων έγινε σε λογιστικό φύλλο Excel. Τα αποτελέσματα έδειξαν ότι υπάρχει μεγάλη ανομοιογένεια σε επίπεδο μεταλλάξεων ανάμεσα στους 21 πληθυσμούς. / Familial hypercholesterolaemia (FH), defined as the heritable occurence of severe hypercholesterolaemia with cholesterol deposits in tendons and premature heart disease, is caused by at least four genes in sterol and lipoprotein pathways and displays varying gene-dose effects. The genes are the low-density lipoprotein (LDL) receptor, apolipoprotein (apo) B, proprotein convertase subtilisin/kexin 9, and the autosomal recessive hypercholesterolaemia (ARH) adaptor protein. The world-wide prevalence of FH is about 1 in 500 people. In this assessment, the genes apoB, PCSK9 and ARH have been excluded. The aim of this study was the recording of LDLR mutations in 21 populations, the calculation of the mutations’ frequencies in each population and the introduction of these data in the National Ethnic Mutation DataBase (NEΜDB), FINDbase, which gives information about a mutation’s frequency in each country and also about its pharmacogenomic marker. Among 21 populations, 14 were of European origin (Greece, Germany, Portugal, Czech Republic, Netherlands, Spain, Great Britain, Italy, Poland, Sweden, France, Austria, Belgium and Denmark) and the remainders from China, Japan, Malaysia, Lebanon, Philippines, Taiwan and Canada. The mutation data in each population were derived from papers through the database of references, PubMed and the search engine, Google. The selection of papers was based on (1) the size of patient group and (2) the date of paper publication. The calculation of mutation frequency was based on the total number of chromosomes, which was the double size of the patient group. An ideal size of sample was at least 100 chromosomes, which means 50 index patients. The data were inserted in an excel file. The results showed that there is a great ανομοιογένεια in mutation level among 21 populations.

Since apoE allele status is the predominant Alzheimers disease (AD) genetic risk factor, functional single nucleotide polymorphisms (SNPs) in brain apoE receptors represent excellent candidates for association with AD. Therefore, three low density lipoprotein receptor (LDLR) SNPs were evaluated by TaqMan allelic discrimination assays for association with AD and I found that certain haplotypes alter the odds of AD. A SNP within LDLR exon 12, rs688, was identified in silico as neutralizing a putative exon splicing enhancer (ESE). Since LDLR is a major apoE receptor in the brain, I hypothesized that rs688 modulates LDLR splicing in neural tissues and associates with AD. To evaluate this hypothesis, I analyzed splicing patterns in human hippocampus samples and established that this SNP was associated with significantly decreased LDLR exon 12 splicing efficiency when the minor allele T is present in vivo. Lastly, I evaluated whether rs688 associates with AD by genotyping DNA from the Religious Orders Study (ROS) series. The rs688T/T genotype was associated with increased AD odds in males, but not in females, in a dataset consisting of 1,457 men and 2,055 women drawn from three case-control series. The rs688T/T genotype was associated with increased AD odds in males (recessive model, odds ratio (OR) of 1.49, 95% confidence interval (CI) of 1.13- 1.97, uncorrected p=0.005), but not in females. In summary, these studies identify a functional apoE receptor SNP that is associated with AD in a sex-dependent fashion.

In vitro studies have shown that the major membrane phospholipid phosphatidylcholine (PC) can positively influence the incorporation of cholesterol in lipid membranes. The influence of PC on the cellular trafficking of LDL-derived free cholesterol was investigated. Sterol regulatory-defective (SRD)-4 cells are Chinese hamster ovary (CHO)-derived fibroblasts that display vastly elevated rates for the synthesis and catabolism of PC. SRD-4 cells harbor two known gene mutations: a mutation in the functional allele for SCAP, resulting in defective feedback suppression of cholesterol biosynthesis; and a loss-of-function mutation in the functional allele for acyl-CoA:cholesterol acyl transferase (ACAT), an endoplasmic reticulum (ER)-localized enzyme that esterifies free cholesterol. Incubation of SRD-4 cells with 50 µg/ml low density lipoprotein (LDL) for 18 h resulted in lysosomal accumulation of free cholesterol as revealed by filipin staining. This accumulation was not evident following LDL treatment of parental CHO7 cells, and was blunted in SRD-2 cells that express a constitutively-active form of SREBP-2 and overproduce cholesterol but have functional ACAT activity. Treatment of SRD-2 cells with LDL in the presence of an ACAT inhibitor 58-035 resulted in robust lysosomal cholesterol accumulation that was reversible upon drug washout, supporting that cholesterol trafficking in cholesterol-loaded cells is dependent on ACAT activity and, more specifically, ER free cholesterol levels. Lysosomal accumulation of LDL-derived cholesterol was prevented in SRD-4 cells supplemented with lyso-PC (50 µM), a substrate for PC synthesis through the reacylation pathway, and also in cells treated with bromoenol lactone (BEL), an inhibitor of phospholipase A2 implicated in bulk PC turnover. In a counter study, lysosomal LDL-derived cholesterol accumulation was induced in parental CHO-7 cells using R-propranolol, which inhibits the conversion of phosphatidic acid to diacylglycerol (DAG), a substrate in the CDP-choline pathway. This blockage was also relieved through co-treatment with lyso-PC. These studies support that PC to free cholesterol ratios in downstream organellar membranes can influence cholesterol trafficking out of lysosomal compartments in cholesterol-loaded cells.

Résumé : Les maladies cardiovasculaires représentent la principale cause de mortalité mondiale, soit le tiers des décès annuels selon l’Organisation mondiale de la Santé. L’hypercholestérolémie, caractérisée par une élévation des niveaux plasmatiques de lipoprotéines de faible densité (LDL), est l’un des facteurs de risque majeur pour les maladies cardiovasculaires. La proprotéine convertase subtilisine/kexine type 9 (PCSK9) joue un rôle essentiel dans l’homéostasie du cholestérol sanguin par la régulation des niveaux protéiques du récepteur LDL (LDLR). PCSK9 est capable de se lier au LDLR et favorise l’internalisation et la dégradation du récepteur dans les lysosomes. L’inhibition de PCSK9 s’avère une cible thérapeutique validée pour le traitement de l’hypercholestérolémie et la prévention des maladies cardiovasculaires. Par contre, plusieurs mécanismes responsables de la régulation et la dégradation du complexe PCSK9-LDLR n’ont pas encore été complètement caractérisés comme la régulation par la protéine annexin A2 (AnxA2), un inhibiteur endogène de PCSK9. De plus, plusieurs évidences suggèrent la présence d’une ou plusieurs protéines, encore inconnues, impliquées dans le mécanisme d’action de PCSK9. Celles-ci pourraient réguler l’internalisation et le transport du complexe PCSK9-LDLR vers les lysosomes. Les objectifs de cette thèse sont de mieux définir le rôle et l’impact de l’AnxA2 sur la protéine PCSK9 en plus d’identifier de nouveaux partenaires d’interactions de PCSK9 pour mieux caractériser son mécanisme d’action sur la régulation des niveaux de LDLR. Nous avons démontré que l’inhibition de PCSK9 par l’AnxA2 extracellulaire s’effectue via sa liaison aux domaines M1+M2 de la région C-terminale de PCSK9 et nous avons mis en évidence les premières preuves d’un contrôle intracellulaire de l’AnxA2 sur la traduction de l’ARNm de PCSK9. Nos résultats révèlent une liaison de l’AnxA2 à l’ARN messager de PCSK9 qui cause une répression traductionnelle. Nous avons également identifié la protéine glypican-3 (GPC3) comme un nouveau partenaire d’interaction extracellulaire avec le PCSK9 et intracellulaire avec le complexe PCSK9-LDLR dans le réticulum endoplasmique des cellules HepG2 et Huh7. Nos études démontrent que GPC3 réduit l’activité extracellulaire de PCSK9 en agissant comme un compétiteur du LDLR pour la liaison avec PCSK9. Une meilleure compréhension des mécanismes de régulation et de dégradation du complexe PCKS9-LDLR permettra de mieux évaluer l’impact et l’efficacité des inhibiteurs de la protéine PCSK9. / Abstract : Cardiovascular disease is the leading cause of global mortality, responsible for one third of global deaths, according to the latest statistics from World Health Organization. Hypercholesterolemia, characterized by increased plasma low-density lipoprotein (LDL) cholesterol, is a major determinant of cardiovascular disease risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in cholesterol homeostasis by regulating LDL receptor (LDLR) protein levels. PCSK9 binds to the LDLR and promotes its internalization and degradation in late endosomal/lysosomal compartments. Inhibition of PCSK9 action on LDLR has emerged as a novel therapeutic target for hypercholesterolemia and the prevention of cardiovascular disease. Annexin A2 (AnxA2) was reported as an endogenous extracellular inhibitor of PCSK9 activity upon cell-surface LDLR degradation and mechanisms of PCSK9’s regulation by AnxA2. However, its role on PCSK9 regulation still need better characterization in hepatocellular carcinoma cell lines. Moreover, many evidences suggest the presence of additional unknown interaction partners involve in the LDLR regulation and degradation mediated by PCSK9. These unknown partners could regulate the internalization and trafficking of the PCSK9-LDLR complex to lysosomes. The objectives of this thesis are to better define the role and impact of AnxA2 on PCSK9 and to identify novel PCSK9 interacting partners that participate and regulate the PCSK9-LDLR complex formation and degradation. We demonstrated that PCSK9 inhibition by extracellular AnxA2 occurs via its interaction with the M1+M2 modules of PCSK9’s C-terminal region. Most importantly, we revealed a new role of intracellular AnxA2 in the reduction of PCSK9 protein levels via a translational mechanism. Our results suggest a translational repression from the binding of AnxA2 to PCSK9’s mRNA. Also, we successfully identified a novel and functional interaction between glypican-3 (GPC3) and PCSK9. We demonstrated the extracellular GPC3 interaction with PCSK9 and the intracellular GPC3 with both PCSK9 and LDLR in human hepatocellular carcinoma cell lines HepG2 and Huh7. Our studies revealed that extracellular GPC3 can act as an endogenous competitive binding partner of PCSK9 to the LDLR, and hence reducing its activity towards LDLR degradation. The continued understanding of PCSK9 interactions is critical, from a mechanistic point of view as well as from the optimization of therapeutic interventions.

In vitro studies have shown that the major membrane phospholipid phosphatidylcholine (PC) can positively influence the incorporation of cholesterol in lipid membranes. The influence of PC on the cellular trafficking of LDL-derived free cholesterol was investigated. Sterol regulatory-defective (SRD)-4 cells are Chinese hamster ovary (CHO)-derived fibroblasts that display vastly elevated rates for the synthesis and catabolism of PC. SRD-4 cells harbor two known gene mutations: a mutation in the functional allele for SCAP, resulting in defective feedback suppression of cholesterol biosynthesis; and a loss-of-function mutation in the functional allele for acyl-CoA:cholesterol acyl transferase (ACAT), an endoplasmic reticulum (ER)-localized enzyme that esterifies free cholesterol. Incubation of SRD-4 cells with 50 µg/ml low density lipoprotein (LDL) for 18 h resulted in lysosomal accumulation of free cholesterol as revealed by filipin staining. This accumulation was not evident following LDL treatment of parental CHO7 cells, and was blunted in SRD-2 cells that express a constitutively-active form of SREBP-2 and overproduce cholesterol but have functional ACAT activity. Treatment of SRD-2 cells with LDL in the presence of an ACAT inhibitor 58-035 resulted in robust lysosomal cholesterol accumulation that was reversible upon drug washout, supporting that cholesterol trafficking in cholesterol-loaded cells is dependent on ACAT activity and, more specifically, ER free cholesterol levels. Lysosomal accumulation of LDL-derived cholesterol was prevented in SRD-4 cells supplemented with lyso-PC (50 µM), a substrate for PC synthesis through the reacylation pathway, and also in cells treated with bromoenol lactone (BEL), an inhibitor of phospholipase A2 implicated in bulk PC turnover. In a counter study, lysosomal LDL-derived cholesterol accumulation was induced in parental CHO-7 cells using R-propranolol, which inhibits the conversion of phosphatidic acid to diacylglycerol (DAG), a substrate in the CDP-choline pathway. This blockage was also relieved through co-treatment with lyso-PC. These studies support that PC to free cholesterol ratios in downstream organellar membranes can influence cholesterol trafficking out of lysosomal compartments in cholesterol-loaded cells.

In vitro studies have shown that the major membrane phospholipid phosphatidylcholine (PC) can positively influence the incorporation of cholesterol in lipid membranes. The influence of PC on the cellular trafficking of LDL-derived free cholesterol was investigated. Sterol regulatory-defective (SRD)-4 cells are Chinese hamster ovary (CHO)-derived fibroblasts that display vastly elevated rates for the synthesis and catabolism of PC. SRD-4 cells harbor two known gene mutations: a mutation in the functional allele for SCAP, resulting in defective feedback suppression of cholesterol biosynthesis; and a loss-of-function mutation in the functional allele for acyl-CoA:cholesterol acyl transferase (ACAT), an endoplasmic reticulum (ER)-localized enzyme that esterifies free cholesterol. Incubation of SRD-4 cells with 50 µg/ml low density lipoprotein (LDL) for 18 h resulted in lysosomal accumulation of free cholesterol as revealed by filipin staining. This accumulation was not evident following LDL treatment of parental CHO7 cells, and was blunted in SRD-2 cells that express a constitutively-active form of SREBP-2 and overproduce cholesterol but have functional ACAT activity. Treatment of SRD-2 cells with LDL in the presence of an ACAT inhibitor 58-035 resulted in robust lysosomal cholesterol accumulation that was reversible upon drug washout, supporting that cholesterol trafficking in cholesterol-loaded cells is dependent on ACAT activity and, more specifically, ER free cholesterol levels. Lysosomal accumulation of LDL-derived cholesterol was prevented in SRD-4 cells supplemented with lyso-PC (50 µM), a substrate for PC synthesis through the reacylation pathway, and also in cells treated with bromoenol lactone (BEL), an inhibitor of phospholipase A2 implicated in bulk PC turnover. In a counter study, lysosomal LDL-derived cholesterol accumulation was induced in parental CHO-7 cells using R-propranolol, which inhibits the conversion of phosphatidic acid to diacylglycerol (DAG), a substrate in the CDP-choline pathway. This blockage was also relieved through co-treatment with lyso-PC. These studies support that PC to free cholesterol ratios in downstream organellar membranes can influence cholesterol trafficking out of lysosomal compartments in cholesterol-loaded cells.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted glycoprotein that promotes degradation of low-density lipoprotein receptors. Gain- and loss-of-function variants of PCSK9 cause hypercholesterolemia and hypocholesterolemia, respectively. Although it has been a decade since the discovery of PCSK9, its effect in terms of global protein changes and interactions still require further understanding. This study provided a global outlook at the protein changes caused by PCSK9 and its variants in human hepatic HUH7 cell line. First, a proteomics-based method for protein subcellular distribution analysis has been developed. Second, through secretome analyses, six apolipoproteins and six proteins involved in the coagulation pathway were found with >2-fold changes between wild type PCSK9 and its variants. Third, through secreted interactome analyses, a list of 159 PCSK9 interactor candidates was identified. Two interacting proteins, FASN and PSMD2, were validated and demonstrated with dynamic interacting patterns between PCSK9 and its variants.

Elevated plasma cholesterol is a risk factor for cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) hinders the uptake of low-density lipoprotein cholesterol (LDL-c) by mediating degradation of LDL receptors (LDLRs) in the liver. Gain-of-function (GOF) mutations in PCSK9 cause familial hypercholesterolemia (FH). In normolipidemic human plasma, 30-40% of PCSK9 is bound to LDL particles, and this association with LDL inhibits PCSK9’s ability to mediate LDLR degradation in cultured cells. To further investigate the physiological relevance of this interaction, we analyzed natural GOF mutations in PCSK9 and assessed their effects in vitro on LDL binding, LDLR binding and LDLR degradation. Our results indicate that several GOF mutations severely inhibit LDL binding compared to wild type (WT) PCSK9, and only modestly affect LDLR affinity and LDLR degradation. These findings shed light on the potential physiological relevance of the PCSK9-LDL interaction, which may have an inhibitory effect on PCSK9 activity in vivo.

Orientadores: Marta Helena Krieger, Regina Celia Spadari-Bratfisch / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-08T07:50:11Z (GMT). No. of bitstreams: 1 Garcia_JoseAntonioDias_D.pdf: 1987747 bytes, checksum: 1ec8d731703522ccf42a42dafd7b13a7 (MD5) Previous issue date: 2006 / Resumo: Recentemente demonstrou-se que S-nitroso-N-acetilcisteína (SNAC) atenua o desenvolvimento da placa de aterosclerose na aorta em cerca de 55% de camundongos deficientes do receptor de lipoproteína de baixa densidade (LDLr-/-). O presente estudo teve como objetivo: i) verificar se a deleção do gene do receptor de LDL pode alterar o perfil hemodinâmico e a resposta inotrópica do coração a agentes adrenérgicos; ii) determinar a capacidade do SNAC na prevenção das alterações estruturais e funcionais do miocárdio e; iii) verificar o efeito do SNAC na pressão arterial de camundongos hipercolesterolêmicos. Camundongos machos C57BL6 (Wild Type = WT) e camundongos LDLr-/- (S) foram alimentados com dieta comercial por 15 dias. Em relação aos camundongos WT, os camundongos S apresentaram aumento de 11% na pressão arterial, diminuição de 62% na contratilidade do átrio esquerdo, e aumento na expressão do CD40L e redução na expressão de NOSe no tecido ventricular esquerdo. Camundongos LDLr-/- alimentados com dieta enriquecida em 1,25% de colesterol, 20% de gordura e 0,5% de ácido cólico por 15dias (Chol) apresentaram hipertrofia ventricular esquerda (HVE) comparados aos camundongos S, a qual foi caracterizada por: a) aumento de 1,25 vezes na razão entre o peso ventricular esquerdo (mg) e o peso corporal (g) (4,17±0,09 vs 3,34±0,07 mg/g, respectivamente; p< 0,05); b) aumento do diâmetro dos cardiomiócitos (25±0,6 vs 19±0,7 µm, p<0.05); c) aumento na expressão das isoformas das NOS (óxido nítrico sintases) e hiperexpressão do CD40L; d) aumento do depósito de colágeno; e) sem alterações na performance contrátil do átrio esquerdo e na responsividade à noradrenalina. A administração do SNAC aos camundongos Chol (chol+SNAC) (0,51 µmol/kg/dia, i.p.), preveniu o aumento na razão do peso ventricular esquerdo (mg) e o peso corporal (g) (3.38±0.23 mg/g), no diâmetro dos cardiomiócitos (20±0.7 µm), no deposito de colágeno, na expressão das isoformas da NOS e a hiperexpressão do CD40L. O SNAC não apresentou efeito no aumento da pressão arterial e nem sobre a hipocontratilidade, mas recuperou a responsividade para noradrenalina. Em conclusão, o presente estudo demonstrou que camundongos com deleção do gene do receptor LDL apresentaram hipertensão e marcada redução contrátil. Essas características podem estar relacionados com o estresse oxidativo resultante do processo inflamatório e da hipoexpressão da NOSe. A dieta hiperlipídica promoveu hipertrofia ventricular esquerda (HVE), devida ao aumento nos processos inflamatório e oxidativo. O SNAC impediu o desenvolvimento da HVE por mecanismos que envolveram efeito antiinflamatório (detectado pela diminuição na expressão do CD40L), a hiperexpressão das NOS, a redução das alterações estruturais ventriculares induzidas pela hipercolesterolemia de maneira independente da hipertensão. No presente estudo, a necessidade de quantificar as análises histológicas exigiu a validação de um software interativo para analisar imagens de amostras teciduais. O software foi projetado para permitir que o usuário altere os tipos de coloração vermelha, verde e azul (RGB) para uma cor padrão que possa ser usada para segmentar a imagem e calcular a fração da área de interesse. Os resultados obtidos com a contagem manual e com a contagem feita com o uso do software foram similares, indicando que são métodos alternativos confiáveis para análises quantitativas de cortes histológicos. Entretanto, o software permite processar as imagens de maneira eficiente e confiável, além de reproduzir o corte tecidual em um menor tempo, e pode ser executado com o microscópio e o computador padrão / Abstract: Recently, it has been that S-nitroso-N-acetylcysteine (SNAC) attenuate in 55% the plaque development in low-density lipoprotein-receptor-deficient (LDLr-/-) mice fed a hypercholesterolemic diet for 15 days. The present study was designed to verify whether deletion of the low-density lipoprotein (LDL) receptor gene may affect the hemodynamic profile and adrenergic inotropic cardiac responses and, particularly, to identify the ability of SNAC to prevent the myocardial alterations and hypertension in hypercholesterolemic mice. C57BL6 wild-type (WT) and LDLr-/- male mice (S) were fed a commercial diet for 15 days. Control mice (S) showed 11 % blood pressure increase, 62% left atrial contractility decrease, CD40L overexpression and eNOS underexpression in comparison to WT. LDLr-/- mice which were fed for 15 days with 1,25% cholesterol, 20% of fat and 0.5% of colic acid enriched diet (Chol), showed significant left ventricular hypertrophy (LVH) versus S, which was characterized by: a) 1.25-fold increase in the LV weight (mg)/body weight (g) ratio (4.17±0.09 vs. 3.34±0.07 mg/g, respectively; p<0.05); b) increased cardiomyocyte diameter (25±0.6 vs. 19±0.7 µm, p<0.05); c) enhanced expression of the constitutive and inducible NOS isoforms and CD40L;d) increased collagen deposit; e) no alteration in the atrial contractile performance or responsiveness to norepinephrine. Administration of SNAC to Chol mice ( Chol +SNAC) (0.51 µmol/kg/day, for 15day, i.p.) prevented increases in the left ventricular weight/body weight ratio (3.38±0.23 mg/g), cardiomyocyte diameter (20±0.7 µm), collagen deposit, NOS isoforms and CD40L overexpression, but had no effect on increased blood pressure or atrial basal hypocontractility, although it recovered responsiveness to norepinephrine. In conclusion, the present study demonstrated that the deletion of the LDL receptor gene in mice determined hypertension and a marked left atrial contractile deficit. These findings may be related to oxidative stress, resulting from inflammation and eNOS underexpression. High-cholesterol diet promoted LVH in LDLr-/- mice associated with enhanced inflammatory and oxidant processes. SNAC prevented LVH by processes that involved decreased CD40L expression and NOS overexpression effects attenuating the ventricular structural alterations induced by hypercholesterolemia independent of hypertension. Histological quantization demanded the development of interactive software for image analysis of tissue samples. The software was designed to allow a user-oriented change of a chosen red, green and blue (RGB) staining in a standardized color that can be used to segment the image and calculate the fractional area of interest. Thus the method allows efficient, reliable and reproducible processing of tissue sections that is less time-consuming than conventional methods and can be performed with standard microscope and computer / Doutorado / Fisiologia / Doutor em Biologia Funcional e Molecular